عرض بسيط للتسجيلة

المؤلفYounis, Nour K
المؤلفYassine, Hadi M
المؤلفEid, Ali H
تاريخ الإتاحة2023-01-29T06:52:25Z
تاريخ النشر2022-12-28
اسم المنشورCurrent Medicinal Chemistry
المعرّفhttp://dx.doi.org/10.2174/0929867330666221228121947
الاقتباسYounis K Nour, Yassine M. Hadi and Eid H Ali*, Nanomedicine for Cancer, Current Medicinal Chemistry 2023; 30() . https://dx.doi.org/10.2174/0929867330666221228121947
الرقم المعياري الدولي للكتاب0929-8673
معرّف المصادر الموحدhttp://hdl.handle.net/10576/38997
الملخصOver the past decades, oncology has occupied the lion’s share of all nanomedical applications [1-3]. In 2020, up to 65% of the clinical trials involving nanomaterials were attending to cancer therapeutics and diagnostics [4]. The focus of most trials is not limited to enhancing the efficacy of available therapeutics or the accuracy and precision of existing diagnostic tools but rather directed to improving the quality of life of cancer patients. Indeed, one approach to overcoming drug resistance can be achieved via modulating the pharmacological characteristics of these therapies [4, 5]. This, in turn, permits their passive and selective delivery to the targeted tumorigenic sites. Furthermore, the use of biocompatible drug delivery systems embracing cancer-specific antibodies facilitates the active delivery of these therapeutics to cancer cells [6].
اللغةen
الناشرBentham Science Publishers
الموضوعNanomedicine
Cancer
العنوانNanomedicine for Cancer.
النوعOther
رقم المجلد30
ESSN1875-533X
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة